Chronic graft-versus-host disease (cGVHD) is a multiorgan disorder and the main cause of transplant related death. Usually, onset of cGVHD occurs within the first 3 years post-transplantation [1] and may linger for several years with devastating effects on patients' quality of life. The original Seattle criteria [2] (Table 1) has been the most frequently used classification of cGVHD despite limitations in describing the extent of the disease, involved organs, and functional impact [1] . A major revision of the cGVHD criteria was published in 2005 by the National Institutes of Health (NIH) Consensus Conference in Clinical Trials in cGVHD (NCC 2005) to standardize cGVHD staging for better diagnosis and to propose a scoring system that includes overall severity as well as organ-oriented information (Table 1) [1, 3] .
Umbilical cord blood (UCB) transplantation is associated with a lower incidence of cGVHD compared to other stem cell sources [3, 4] . However, most studies applying the NCC 2005 criteria include only a limited number of patients transplanted with UCB and/or involve a mixed population of adults and children [4, 5] .
The purpose of the current study is to describe cGVHD according to the NCC 2005 criteria [1] in adult patients who received double UCB transplantation (dUCBT) for hematologic malignancies using data from the Eurocord registry.
Eligible patients were those ≥18 years receiving unmanipulated, unrelated dUCBT (first allogeneic transplantation) for hematologic malignancies in European Society for Blood and Marrow Transplantation (EBMT) center between 2006 and 2012. Other inclusion criteria for the study were neutrophil engraftment, survival ≥100 days, and development of cGVHD post-dUCBT.
Three-hundred and twenty-nine patients met the initial study criteria, but data for cGVHD classification according to NCC 2005 were available for 154 of those.
Patients or legal guardians provided informed consent for the use of data for research purposes. The study was performed in compliance to the Declaration of Helsinki. Standard EBMT definitions for neutrophil and platelet engraftment, myeloablative (MAC) and reduced-intensity (RIC) conditioning regimens, and acute GVHD (aGVHD) were considered. Donor-recipient human leukocyte antigen (HLA) matching was defined as antigenic level for HLA-A and -B and allelic level for HLA-DRB1, considering the cord blood unit with the higher number of disparities with the recipient.
Global scoring was calculated when cGVHD of one or more of the following eight major organs was reported: 'skin', 'mouth', 'eyes', 'gastrointestinal tract (GI tract)', Global scoring was performed in two steps. First, each affected organ was assigned a score of 0-3 according to the extent of cGVHD severity (with 3 being assigned to the most severe manifestation). Next, organ-specific scores were combined to compose the global cGVHD severity grading system [1].
Median follow-up for surviving patients was 44.5 (9.7-103.1) months. Patient and transplant characteristics are described in Table 2 . Most patients (82%) received a combination of calcineurin inhibitor and mycophenolate mofetil for GVHD prophylaxis. The most common conditioning regimen (in both RIC and MAC settings) was cyclophosphamide (CY) and fludarabine (FLU) with total body irradiation (TBI) (70%). Compared to previous studies on UCBT, our cohort is relatively homogenous in terms of conditioning regimen and cGVHD prophylaxis, probably due to the general acceptance of the Minnesota protocol for dUCBT [6] .
Most patients (89%) achieved full donor chimerism within the first 100 days after dUCBT.
One-hundred and fifteen (75%) patients had aGVHD (any grade) before cGVHD, from those 88 had grade II-IV aGVHD. This is consistent with the literature that reports around 30% of cGVHD as de novo cases [3, 7] .
In our study, overlapping was reported in 30% of the cases whereas other studies have described it in around 50-70% of patients [4, 8] . Overlapping GVHD may be a transient condition and, therefore, not always consistently reported to clinical registries.
NCC 2005 global scores were mild in 43.5% (n = 67), moderate in 34.4% (n = 53), and severe in 21.4% (n = 33). Most patients (90%) were diagnosed with cGVHD within Variables with missing observations: disease status at dUCBT for acute leukemia n = 1; ABO mismatch n = 20; (Donor, Donor)-Recipient gender mismatch n = 2; HLA mismatch n = 30; relapse n = 1 * n = 153; global score not calculated for 1 patient ** Advanced = non CR/relapse/3 or >3 CR *** Mostly cyclosporin-A (n = 121) the first year in a median time of 5 (range: 1.6-67.6) months after dUCBT. Most patients (n = 86; 56%) had only one organ involvement. The combinations of organ involvement are listed in Table 2 . Skin was the most commonly affected organ, both as single site (39%) or in combination with other organ/s (77%). Seven patients had >3 organ involvement (4.6%), with a maximum of five affected organs. Out of these patients, three achieved resolution of cGVHD during the follow-up period.
Out of the 58 patients who experienced cGVHD of the GI tract, 40 had a previous history of grade II-IV aGVHD of the same organ. Other studies have reported a relatively higher incidence of GI aGVHD in dUCBT compared to other stem cell sources [9] . The design of our study prevents us from making inferences regarding the impact of aGVHD on incidence and severity of cGVHD.
Most patients with mild (78%) and moderate (68%) scores achieved cGVHD resolution during the follow-up period, compared to only 30% of the patients with severe score. The most frequently reported systemic treatment was steroids (81%). Patients with mild global score received, mostly, topical or no treatment. Forty-six (30%) patients received second-line treatment for cGVHD. Second-line treatment was very heterogeneous, reflecting the lack of consensus on the effectiveness of treatments for corticosteroid-resistant cGVHD [3] .
Chronic GVHD resolved in 61% (n = 94) of the patients. A previous study suggested that GVHD after single UCB transplantation (sUCBT) might be more easily manageable than after transplant with other stem cell source [10] . However, the observation reported in the previous study was based on aGVHD after sUCBT, while we report cGVHD after dUCBT. Nevertheless, it is biologically plausible that the naivety of lymphocytes of the UCB graft that mitigates aGVHD may also be applicable to cGVHD in this setting, supporting the high cGVHD resolution rates observed in our study.
Forty-five patients relapsed (30%), most (n = 38) after the diagnosis of cGVHD. This may imply that cGVHD treatment with immunosuppressive drugs may have contributed to relapse. Some studies suggest that cGVHD might also be implicated in graft-versus-leukemia effect and in comparison with sUCBT, dUCBT would possibly provide better protection from disease recurrence [11] . A balance between disease control and the use immunosuppressive therapy is difficult to find. If on one hand cGVHD may decrease the risk of relapse, it increases the risk of non-relapse related mortality, therefore counteracting the possible benefits in survival [12] . Moreover, the prolonged use of steroids may lead to immune function impairment, avascular necrosis, diabetes, hypertension, or other complications [13] .
Sixty patients (40%) died during the follow-up period and the leading cause of death was disease progression (n = 28; 47%). Twenty-seven patients died of transplant related causes, including 11 cases of cGVHD. Nine out of the 11 patients who died of GVHD had severe global score.
A limitation of this study was the possibility of selection bias due to the exclusion of patients with cGVHD who lacked information for the NCC 2005 classification. However, we feel confident that the population excluded did not differ considerably from the study population, as preliminary analyses comparing major outcomes and general characteristics yielded similar results.
Since the release of the NCC 2005, many questions have been raised about this new set of standards, and surveys have been performed to investigate controversy points and to make recommendations for future revisions. In fact, revised guidelines were released by the NIH in 2014 aiming, mostly, to clarify some areas of confusion and also to emphasize the causes of organ-specific issues [14] . Nevertheless, the overall concept and objectives of the two sets of guidelines remained the same. For our study, we used the NCC 2005 revision to be in agreement with the inclusion period set out for our analysis.
One topic of controversy addressed in the NCC 2014 revision was that organ dysfunction that could be entirely attributed to other conditions should not be considered when scoring cGVHD [3] . Aki et al. reported that these types of confounders could cause misclassification of approximately 10% to a higher score of global severity, mostly in patients with liver and/or lung involvement [15] . In our survey, lung and/or liver involvement were reported only in a few patients; therefore, the impact of these potential confounders in the global classification reported would have been minimal.
This retrospective study provides a comprehensive overview of the organ-specific manifestations and severity of cGVHD for patients undergoing dUCBT. This survey may help physicians to have a better understanding of the most common manifestations of cGVHD reported in this setting.
